☰
Skip to content
Home
Studies
BioFINDER One
BioFINDER Two
BioFINDER Sleep
BioFINDER Preclinical AD
BioFINDER Primary Care
BioFINDER Memory Clinic
Study Group
Publications
News
För allmänheten
BrainWise
Delta i våra studier
Performance of Different Amyloid Immunoassays in Predicting Outcome of Visual Assessment of Amyloid PET Imaging
2017
JAMA Neurology (in press).
Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K, Hansson O.
2026
The Role of Clinical, Plasma, and Imaging Biomarkers in Assessing Future Dementia Risk in Individuals With Subjective Cognitive Decline
2026
Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease
2026
Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer’s disease
2026
Clinical staging in Swedish primary care using the Amsterdam Instrumental Activities of Daily Living Questionnaire.
2026
Comparability of Centiloid values from [18F]flutemetamol scans using seven commercial and research software
2026
Neuropathological correlates of age and sex differences in 18F-flortaucipir PET.
2026
Amyloid beta pathology induces astrocytic pTDP-43 mislocalization and disrupts TDP-43-regulated cryptic exon transcripts.
2026
Trajectories of plasma and CSF MTBR-tau243 and phosphorylated-tau species across the Alzheimer’s disease continuum.
2026
Target product profiles for treatments to delay or prevent symptomatic Alzheimer’s disease
2026
Free Sugar Intake and Dementia Risk: A Swedish Cohort Study on Dietary Sources and Dementia Subtypes.
2026
A deep joint-learning proteomics model for diagnosis of six conditions associated with dementia
2026
Brain network dynamics determine tau presence while regional vulnerability governs tau load in Alzheimer’s disease.
2026
Eligibility for amyloid targeting therapies among primary care patients with cognitive symptoms
2026
Integration of plasma eMTBR-tau243 and p-tau217 in the diagnosis and stratification of Alzheimer’s disease: a prospective cohort study
2026
Identification of distinct and shared biomarker panels in different manifestations of cerebral small-vessel disease through proteomic profiling